Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01989143 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.
A Phase 1 study, sponsored by Telavant.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT01989143 is a Phase 1 study that has completed, run by Telavant. The registered enrollment target is 92 participants.
The verdict
NCT01989143, a Phase 1 study, has completed, sponsored by Telavant.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
This single and multiple ascending dose study is a first in human assessment of PF-06480605. The goal is to study the safety, tolerability, pharmacokinetics and pharmacodynamics.
Interventions
- DRUG Placebo
- DRUG PF-06480605
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01989143
The ClinicalTrials.gov registry entry for NCT01989143 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telavant, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01989143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01989143 about?
NCT01989143 is a clinical study titled "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.". This single and multiple ascending dose study is a first in human assessment of PF-06480605. The goal is to study the safety, tolerability, pharmacokinetics and pharmacodynamics.
What is the current status of trial NCT01989143?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2013-12. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01989143?
The interventions under investigation include: Placebo (DRUG), PF-06480605 (DRUG).
Who is sponsoring clinical trial NCT01989143?
This trial is sponsored by Telavant, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.